VODG Vitro Diagnostics
Company profile
Ticker
VODG
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Bio-Techne • Enzon Pharmaceuticals • Denali Therapeutics • Allogene Therapeutics ...
Former names
LABTEK INC, IMPERIAL MANAGEMENT INC
SEC CIK
Corporate docs
IRS number
841012042
Investment data
Securities sold
Number of investors
Calendar
21 Sep 16
13 Apr 21
31 Oct 21
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
afflicted, attorney, Australia, authentication, banking, Brook, Brooke, capable, cardiac, cartilage, CBV, cellar, computed, corrected, deductible, deposited, destroy, disorder, downturn, driven, dynamic, eastern, EMA, emphasizing, enzymatic, epigenetic, etiology, exemption, expedite, extraction, fat, fraction, FY, genome, guide, hip, immunosuppression, immunosuppressive, immunotherapy, incapable, IND, inflammation, injection, intervention, Kingdom, knee, liposuction, MandA, manipulation, manner, mediate, modulation, neuroprotection, NutraVivo, OA, pain, phenotypic, physical, political, preliminary, problem, procedure, proceeding, provision, red, rehabilitation, remediated, renal, retrospective, screening, specialty, spectrum, strict, stromal, study, supersede, SVF, theCompany, UK, unearned, unrest, unsecured, unsustained, upcoming, vascular, vigorously, white, witnessed
Removed:
abandoned, abbreviated, area, arose, assay, avoiding, behalf, beta, carried, Catalog, choice, classic, compensated, confirmed, consultation, controlling, demonstration, design, DNA, element, elevated, environmental, eradication, erik, eventually, fate, fee, forgive, gatekeeper, gene, gland, glucose, horn, inducing, insulin, lapsed, licensee, lung, master, MN, newly, personalized, pituitary, pledge, pluripotentiality, positioning, privately, project, promote, reconciliation, reprogrammed, reversal, RNA, robust, royalty, satisfaction, skin, somatic, supplier, synthesize, tissue, twelve, van, version
Financial reports
10-K
2015 FY
Annual report
21 Sep 16
10-Q
2015 Q3
Quarterly report
29 Mar 16
10-Q
2015 Q2
Quarterly report
21 Jan 16
10-Q
2015 Q1
Quarterly report
23 Mar 15
NT 10-Q
Notice of late quarterly filing
18 Mar 15
10-K
2014 FY
Annual report
12 Feb 15
NT 10-K
Notice of late annual filing
28 Jan 15
10-Q
2014 Q3
Quarterly report
21 Sep 14
NT 10-Q
Notice of late quarterly filing
11 Sep 14
10-Q
2014 Q2
Quarterly report
18 Jun 14
Current reports
8-K
Vitro Biopharma 3rd Quarter ended July 31st 2020 Financial Results of Operations
5 Oct 20
8-K
Other Events
5 Oct 20
8-K
Vitro Biopharma 2nd Quarter ended April 30th 2020 Financial Results of Operations
9 Jul 20
8-K
Vitro Biopharma Signs MOU with GIOSTAR for COVID-19 IND Using AlloRx Stem Cells
4 Jun 20
8-K/A
Results of Operations and Financial Condition
4 Feb 20
8-K
Results of Operations and Financial Condition
27 Jan 20
8-K
Vitro Biopharma 2nd Quarter ended April 30th 2019 Financial Results of Operations
20 Jun 19
8-K
Vitro Biopharma 1st Quarter ended January 31st 2019 Financial Results of Operations
25 Mar 19
8-K
Results of Operations and Financial Condition
29 Jan 19
8-K
Changes in Registrant's Certifying Accountant
12 Dec 18
Registration and prospectus
D/A
$3.5M in equity / options, sold $1M, 10 investors
8 Oct 20
D
$1M in equity / options, sold $500K, 4 investors
23 Jan 20
D
$30K in equity, sold $30K, 2 investors
29 Sep 10
D
$87.5K in equity / securities to be acquired, sold $87.5K, 3 investors
5 Jan 10
REGDEX
Notice of sale of securities
13 Feb 08